These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 10638219)

  • 1. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological effects of HMG-CoA reductase inhibitors].
    Tomita N; Morishita R; Ogihara T
    Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C; Keane WF
    Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
    Essig M; Vrtovsnik F; Friedlander G
    Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
    Igel M; Sudhop T; von Bergmann K
    Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
    Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
    Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.